LNAI 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-15

• Lunai Bioworks Inc. is an AI-driven biotechnology company focused on precision medicine, biomarker discovery, and therapeutic development for CNS disorders, biodefence, and other serious diseases with unmet medical need. The Company, through the Renovaro Biosciences and BioSymetrics subsidiaries, co…

• We are a pre-clinical biotechnology and artificial intelligence driven healthcare technology company. Our therapeutic and core diagnostic product candidates remain pre-clinical and have not generated any product revenue. During the three and nine months ended March 31, 2026, we recognized $20,942 of…

• Our operating expenses for the three months ended March 31, 2026 and 2025, were $1,448,202 and $4,162,492 respectively, representing a decrease of $2,714,290 or approximately 65%. The decrease in operating expenses primarily relates to the decrease in general and administrative expenses of $2,803,33…

• General and administrative expenses for the three months ended March 31, 2026, and 2025, were $1,421,255 and $4,224,590, respectively, representing a decrease of $2,803,335 or approximately 66%. The variance is primarily related to a decrease in legal expenses of $269,536, compensation and related e…

• General and administrative expenses for the nine months ended March 31, 2026, and 2025, were $5,597,980 and $13,878,963, respectively, representing a decrease of $8,280,982 or approximately 60%. The variance is related to a decrease in consulting fees expense of $2,016,801, legal expenses of $1,885,…

相对上期删除的文字 · 来源:10-Q · 2026-02-17

• December 31, Increase/(Decrease) December 31, Increase/(Decrease)

• We are a pre-revenue, pre-clinical biotechnology and artificial intelligence driven healthcare technology company. We have never generated revenues and have incurred losses since inception. We do not anticipate earning any revenues until our therapies or products are approved for marketing and sale.

• Our operating expenses for the six months ended December 31, 2025 and 2024, were $5,131,774 and $57,884,869 respectively, representing a decrease of $52,753,095, or approximately 91%. The decrease in operating expenses primarily relates to the decrease in goodwill impairment of $47,614,729, general …

• General and administrative expenses for the three months ended December 31, 2025, and 2024, were $1,766,210 and $4,353,123, respectively, representing a decrease of $2,586,913 or approximately 59%. The variance is primarily related to a decrease in legal expenses of $717,092, compensation and relate…

• General and administrative expenses for the six months ended December 31, 2025, and 2024, were $4,176,726 and $9,654,373, respectively, representing a decrease of $5,477,647 or approximately 57%. The variance is related to a decrease in consulting fees expense of $1,960,495, legal expenses of $1,616…

相对上期新增的文字 · 来源:10-Q · 2026-05-15

• (a) The information set forth in Note 11 (Subsequent Events) regarding the May 11, 2026 filing of the civil action against alleged naked short sellers

• During the quarter ended March 31, 2026, no director or Section 16 officer adopted, modified, or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408(a) of Regulation S-K).

相对上期删除的文字 · 来源:10-Q · 2026-02-17

• During the quarter ended December 31, 2025, no director or Section 16 officer adopted, modified, or terminated any “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement” (in each case, as defined in Item 408(a) of Regulation S-K).